The global overactive bladder treatment market is expected to grow at a CAGR of 2.4% in the first half of the forecast period. In 2017, the prescription drugs segment held 96% of the market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 161-page report you will receive 136 charts– all unavailable elsewhere.
The 161-page report provides clear detailed insight into the global overactive bladder treatment market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Overactive Bladder Treatment market forecasts from 2018-2028
• This report also breaks down the revenue forecast for the global overactive bladder treatment market by these submarkets:
• Prescription Drugs Market Forecast 2018-2028
• OTC Drugs Market Forecast 2018-2028
• Short-term Therapy Market Forecast 2018-2028
• Long-term Therapy Market Forecast 2018-2028
• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• US
• EU5: Germany, France, UK, Italy, Spain
• BRIC: Brazil, Russia, India, China
• Japan
• RoW: South Korea, Australia, Canada, MENA, Others
• Our study gives qualitative analysis of the overactive bladder treatment market:
• Drivers and Restraints
• Porter’s Five Forces Analysis
• SWOT Analysis
• Trends and Opportunities
• Reimbursement scenarios in the US, Europe and Japan
• Our study discusses the selected leading companies that are the major players in the overactive bladder treatment market:
• Allergan
• Apotex
• Astellas
• Medtronic
• Mylan
• Pfizer
• Sanofi
Visiongain’s study is intended for anyone requiring commercial analyses for the global overactive bladder treatment market. You find data, trends and predictions.
Buy our report today Global Overactive Bladder Treatment Market 2018-2028: Prescription Drugs, OTC Drugs, Short-term Therapy, Long-term Therapy.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2. Introduction to Overactive Bladder
2.1 Available Diagnosis for Overactive Bladder Symptoms
2.1.1 Urinalysis
2.1.2 Urodynamic Tests
2.1.3 Uroflowmetry
2.1.4 Cough Stress Test
2.1.5 Prostate or Pelvic exam
2.1.6 Cystourethrogram
2.2 Class of Drugs
2.2.1 Anti-muscarinic Agent
2.2.2 Beta-3-Adrenergic Receptor Agonist
2.3 Available Treatments for Overactive Bladder
2.3.1 Behavioural Therapy
2.3.2 Pelvic Floor Physiotherapy
2.3.3 Electrical Stimulation
2.4 The Prevalence and Burden of Overactive Bladder
2.5 Drug Profiles
2.5.1 Darifenacin
2.5.2 Fesoterodine
2.5.3 Worldwide Sales of Toviaz 2016 vs 2017
2.5.4 Oxybutynin
2.5.5 Solifenacin
2.5.6 Tolterodine
2.5.7 Trospium
2.5.8 Botox Injection
3. Global Overactive Bladder Therapeutic Market Forecast 2018-2028
4. Global Overactive Bladder Therapeutic Market 2018-2028: Submarket Segmentation by Prescription and OTC Drugs
4.1 Forecast by Prescription vs OTC Drugs 2018-2028
4.1.1 Global Overactive Bladder Prescription Drugs Market 2018-2028
4.1.2 Global Overactive Bladder OTC Drugs Market 2018-2028
4.1.3 Market Share Forecast - Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2018-2028
5. Global Overactive Bladder Therapeutic Market 2018-2028: Submarket Segmentation by Duration of Therapy 2018-2028
5.1 Forecast by Duration of Therapy 2018-2028
5.2 Global Overactive Short-term Overactive Bladder Therapy Market 2018-2028
5.3 Global Overactive Bladder Long-term Therapy Market 2018-2028
5.4 Market Share Forecast by Duration of Therapy 2018-2028
6. Global Overactive Bladder Therapeutic Market: Drivers, Restraints and Trends
7. Global Overactive Bladder Therapeutic Market 2018-2028: Leading National Markets
7.1 Geographical Breakdown of Global Overactive Bladder Therapeutic Market, 2017
7.1.1 Breakdown of Global Overactive Bladder Therapeutic Market by Region, 2017
7.1.2 Breakdown of Global Overactive Bladder Therapeutic Market by Country, 2017
7.1.3 Region-wise Forecast of Global Overactive Bladder Therapeutic Market, 2018-2028
7.2 Global Overactive Bladder Therapeutic Market in the US, 2017
7.2.1 Healthcare Scenario in the US
7.2.2 Economic Impacts of Overactive Bladder
7.2.3 US Overactive Bladder Therapeutic Market 2018-2028
7.3 EU5 Overactive Bladder Therapeutic Market 2018-2028
7.3.1 The UK Overactive Bladder Therapeutic Market 2018-2028
7.3.2 Germany Overactive Bladder Therapeutic Market 2018-2028
7.3.3 France Overactive Bladder Therapeutic Market 2018-2028
7.3.4 Italy Overactive Bladder Therapeutic Market 2018-2028
7.3.5 Spain Overactive Bladder Therapeutic Market 2018-2028
7.4 BRIC Overactive Bladder Therapeutic Market 2018-2028
7.4.1 Brazil Overactive Bladder Therapeutic Market 2018-2028
7.4.2 Russia Overactive Bladder Therapeutic Market 2018-2028
7.4.3 China Overactive Bladder Therapeutic Market 2018-2028
7.4.4 India Overactive Bladder Therapeutic Market 2018-2028
7.5 Japan Overactive Bladder Therapeutic Market 2018-2028
7.6 Australia Overactive Bladder Therapeutic Market 2018-2028
7.7 Canada Overactive Bladder Therapeutic Market 2018-2028
8. Global Overactive Bladder Therapeutic Market: Leading Companies
8.1 Competitive Scenarios
8.2 Astellas
8.3 Pfizer
8.4 Allergan
8.5 Sanofi
8.6 Medtronic
8.7 Apotex
8.8 Mylan
9. Drugs to Treat Overactive Bladder
10. Global Overactive Bladder Therapeutic Market: Qualitative Analysis
10.1 SWOT Analysis
10.2 Porter’s Five Forces Analysis
10.3 Overall Global Overactive Bladder Therapeutic Market Drivers
10.3.1 Number of Elderly Patients Expected to Rise
10.3.2 Opportunities from the Long Pipeline Will Drive Growth
10.3.3 Focus on early diagnosis will increase the number of patients in the market
10.4 Restraints on Growth in the Overactive Bladder Therapeutic Market
10.4.1 Low Awareness
10.4.2 Competition from Generics Will Increase
10.4.3 High Number of Products Will Saturate Market
10.4.4 Lack of reimbursement for Diagnosis and therapeutic products will hinder the market growth
10.5 Opportunities on Growth in the Overactive Bladder Therapeutic Market
10.5.1 Need for Effective Drugs with Better Safety Profiles
10.6 Reimbursement
10.6.1 NICE (UK)
10.6.2 SMC (Scotland)
10.6.3 PBAC (Australia)
10.6.4 CADTH (Canada)
10.6.5 G-BA (Germany)
10.6.6 HAS (France)
10.7 Reimbursement Scenarios in various Countries
10.7.1 Japan
10.7.2 The US
10.7.3 Europe
11. Overactive Bladder Therapeutic Market: Other Prominent Vendors
12. Conclusion
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 3.1 Global Overactive Bladder Therapeutic Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 4.1 Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 4.2 Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017-2028: AGR (%)
Table 4.3 Global Overactive Bladder Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 4.4 Global Overactive Bladder OTC Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 4.5 Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2018-2028: Market Share (%)
Table 5.1 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 5.2 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy 2017-2028: AGR (%)
Table 5.3 Global Overactive Bladder Short-term Therapy Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 5.4 Global Overactive Bladder Long-term Therapy Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 5.5 Global Overactive Bladder Therapeutic Market by Duration of Therapy 2017-2028: Market Share Forecast 2018-2028 (%)
Table 7.1 Global Overactive Bladder Therapeutic Market by Region: Revenue ($m), and Market Share (%), 2017
Table 7.2 Global Overactive Bladder Therapeutic Market by Country: Revenue ($m), and Market Share (%), 2017
Table 7.3 Global Overactive Bladder Therapeutic Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.4 Global Overactive Bladder Therapeutic Market by Region: AGR 2017-2028 (%)
Table 7.5 Global Overactive Bladder Therapeutic Market Forecast 2017-2028: AGR (%)
Table 7.6 Overactive Bladder Therapeutic Market Forecast in the US 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 7.7 EU Overactive Bladder Therapy Market by Country 2017: Revenue ($m), Market Share (%)
Table 7.8 Overactive Bladder Therapeutic Market Forecast in EU5 Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.9 Overactive Bladder Therapeutic Market by EU Region: Market Share Forecast 2018-2028 (%)
Table 7.10 Overactive Bladder Therapeutic Market Forecast by EU5 Region:
Table 7.11 Overactive Bladder Therapeutic Market Forecast by EU5 Region: AGR (%) -2017-2028
Table 7.12 Overactive Bladder Therapeutic Market Forecast in the UK: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.13 Overactive Bladder Therapeutic Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.14 Overactive Bladder Therapeutic Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.15 Overactive Bladder Therapeutic Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.16 Overactive Bladder Therapeutic Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.17 Overactive Bladder Therapeutic Market Forecast in BRIC Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.18 Overactive Bladder Therapeutic Market Forecast in Brazil Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.19 Overactive Bladder Therapeutic Market Forecast in Russia: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.20 Overactive Bladder Therapeutic Market Forecast in China: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.21 Overactive Bladder Therapeutic Market Forecast in India: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.22 Overactive Bladder Therapeutic Market Forecast in Japan: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.23 Overactive Bladder Therapeutic Market Forecast in Australia: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.24 Overactive Bladder Therapeutic Market Forecast in Canada: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 8.1 Astellas: Company Overview
Table 8.2 Pfizer: Company Overview
Table 8.3 Sanofi: Company Overview
Table 8.4 Medtronic: Company Overview
Table 8.5 Medtronic Revenue FY2013 – FY2017
Table 8.6 Medtronic: Urological and Urogynecological Products
Table 8.7 Apotex: Company Overview
Table 8.8 Mylan: Company Overview
Table 9.1 Drugs to Treat Overactive Bladder
Table 10.1 HTA Agencies
Table 11.1 Other Prominent Vendors
List of Figures
Figure 2.1 Prevalence of Overactive Bladder Syndrome versus Other Health Conditions
Figure 2.2 Sales ($m) of Toviaz 2016 versus 2017
Figure 3.1 Global Overactive Bladder Therapeutic Market 2017-2028: Revenue ($m), AGR (%)
Figure 4.1 Global Market Segmentation by Prescription and OTC Drugs, Revenue 2017 ($m)
Figure 4.2 Global Market Segmentation by Prescription and OTC Drugs, Revenue 2017 (%)
Figure 4.3 Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017-2028: Revenue ($m)
Figure 4.4 Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs, Market share 2017 (%)
Figure 4.5 Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017, 2023 and 2028: Revenue ($m)
Figure 4.6 Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017-2028: AGR (%)
Figure 4.7 Global Overactive Bladder Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%)
Figure 4.8 Global Overactive Bladder OTC Drugs Market 2017-2028: Revenue ($m), AGR (%)
Figure 4.9 Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2018-2028: Market Share (%)
Figure 4.10 Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2017 (%)
Figure 4.11 Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2023 (%)
Figure 4.12 Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2028 (%)
Figure 5.1 Global Overactive Drugs Market Segmentation by Duration of Therapy, Revenue 2017 ($m)
Figure 5.2 Global Overactive Drugs Market Segmentation by Duration of Therapy, Revenue 2017 (%)
Figure 5.3 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy 2017-2028: Revenue ($m)
Figure 5.4 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy: Revenue ($m) 2017 and 2028
Figure 5.5 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy 2017-2028: AGR (%)
Figure 5.6 Global Overactive Bladder Short-term Therapy Market 2017-2028: Revenue ($m), AGR (%)
Figure 5.7 Global Overactive Bladder Long-term Therapy Market 2017-2028: Revenue ($m), AGR (%)
Figure 5.8 Global Overactive Bladder Therapeutic Market by Duration of Therapy 2017: Market Share (%)
Figure 5.9 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy, Market Share Forecast 2017, 2023, 2028 (%)
Figure 5.10 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy, Market Share Forecast 2017 (%)
Figure 5.11 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy, Market Share Forecast 2023 (%)
Figure 5.12 Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy, Market Share Forecast 2028 (%)
Figure 6.1 Trends in Global Overactive Bladder Therapeutic Market
Figure 6.2 Trends in Global Overactive Bladder Therapeutic Market
Figure 7.1 Global Overactive Bladder Therapeutic Market Segmentation by Region/Country
Figure 7.2 Global Overactive Bladder Therapeutic Market by Region: Revenue ($m)
Figure 7.3 Global Overactive Bladder Therapeutic Market by Region: Market Share 2017 (%)
Figure 7.4 Global Overactive Bladder Therapeutic Market by Country: Revenue ($m)
Figure 7.5 Global Overactive Bladder Therapeutic Market by Country: Market Share (%)
Figure 7.6 Global Overactive Bladder Therapeutic Market Forecast by Region: Revenue ($m), 2017-2028
Figure 7.7 Global Overactive Bladder Therapeutic Market Forecast by Region 2017, 2023, 2028: Revenue ($m)
Figure 7.8 Global Overactive Bladder Therapeutic Market by Region: AGR 2017-2028 (%)
Figure 7.9 Global Overactive Bladder Therapeutic Market Forecast 2017-2028: AGR (%)
Figure 7.10 Global Overactive Bladder Therapeutic Market Share Forecast 2018 (%)
Figure 7.11 Global Overactive Bladder Therapeutic Market Share Forecast 2023 (%)
Figure 7.12 Global Overactive Bladder Therapeutic Market Share Forecast 2028 (%)
Figure 7.13 Overactive Bladder Therapeutic Market in the US: Market Share (%), 2017
Figure 7.14 Overactive Bladder Therapeutic Market Forecast in the US 2017-2028: Revenue ($m), AGR (%)
Figure 7.15 Overactive Bladder Therapeutic Market in the EU5 2017: Global Market Share (%)
Figure 7.16 Overactive Bladder Therapeutic Market in the EU5 Countries 2016: Market Share (%)
Figure 7.17 Overactive Bladder Therapeutic Market Forecast in the EU5 2017-2028: Revenue ($m), AGR (%)
Figure 7.18 Overactive Bladder Therapeutic Market Forecast in EU5 Region: Revenue 2017-2028: Revenue ($m)
Figure 7.19 Overactive Bladder Therapeutic Market Forecast in the EU5 Countries 2017 and 2028: Revenue ($m)
Figure 7.20 Overactive Bladder Therapeutic Market by EU5 Region: Market Share Forecast 2018-2028 (%)
Figure 7.21 Overactive Bladder Therapeutic Market in the EU5 2028: Global Market Share (%)
Figure 7.22 Overactive Bladder Therapeutic Market Forecast by EU5 Region: Market Share 2017(%)
Figure 7.23 Overactive Bladder Therapeutic Market Forecast by EU5 Region: Market Share 2023 (%)
Figure 7.24 Overactive Bladder Therapeutic Market Forecast by EU5 Region: Market Share 2028 (%)
Figure 7.25 Overactive Bladder Therapeutic Market Forecast by EU5 Region
Figure 7.26 Overactive Bladder Therapeutic Market Forecast by EU5 Region: AGR 2017-2028 (%)
Figure 7.27 Overactive Bladder Therapeutic Market Forecast in the UK: Revenue ($m), AGR (%), 2017-2028
Figure 7.28 Overactive Bladder Therapeutic Market Forecast in Germany: Revenue ($m), AGR (%), 2017-2028
Figure 7.29 Overactive Bladder Therapeutic Market Forecast in France: Revenue ($m), AGR (%), 2017-2028
Figure 7.30 Overactive Bladder Therapeutic Market Forecast in Italy: Revenue ($m), AGR (%), 2017-2028
Figure 7.31 Overactive Bladder Therapeutic Market Forecast in Spain: Revenue ($m), AGR (%), 2017-2028
Figure 7.32 Overactive Bladder Therapeutic Market Forecast in the BRIC Countries 2017-2028: Revenue ($m)
Figure 7.33 Overactive Bladder Therapeutic Market Forecast in the BRIC Countries: Revenue ($m) 2017, 2013 and 2028:
Figure 7.34 Overactive Bladder Therapeutic Market Forecast by BRIC Region: Global Market Share 2017(%)
Figure 7.35 Overactive Bladder Therapeutic Market Forecast by BRIC Region: Market Share 2017 (%)
Figure 7.36 Overactive Bladder Therapeutic Market Forecast by BRIC Region: Market Share 2028 (%)
Figure 7.37 Overactive Bladder Therapeutic Market Forecast by BRIC Region: Global Market Share 2028(%)
Figure 7.38 Overactive Bladder Therapeutic Market Forecast in Brazil: Revenue ($m), AGR (%), 2017-2028
Figure 7.39 Overactive Bladder Therapeutic Market Forecast in Russia: Revenue ($m), AGR (%), 2017-2028
Figure 7.40 Overactive Bladder Therapeutic Market Forecast in China: Revenue ($m), AGR (%), 2017-2028
Figure 7.41 Overactive Bladder Therapeutic Market Forecast in India: Revenue ($m), AGR (%), 2017-2028
Figure 7.42 Overactive Bladder Therapeutic Market in Japan: 2017 Revenue ($m), Market Share %
Figure 7.43 Overactive Bladder Therapeutic Market Forecast in Japan: Revenue ($m), AGR (%), 2017-2028
Figure 7.44 Overactive Bladder Therapeutic Market in Australia: 2017 Revenue ($m), Market Share %
Figure 7.45 Overactive Bladder Therapeutic Market Forecast in Australia: Revenue ($m), AGR (%), 2017-2028
Figure 7.46 Overactive Bladder Therapeutic Market in Canada: 2017 Revenue ($m), Market Share %
Figure 8.1 Astellas Sales by Geographic area, Market Share (%), 2017
Figure 8.2 Astellas Sales by Therapeutic area, Market Share (%), 2017
Figure 8.3 Astellas: SWOT Analysis
Figure 8.4 Sales of Pfizer by Geographical region
Figure 8.5 Pfizer: SWOT Analysis
Figure 8.6 Allergan: SWOT Analysis
Figure 8.7 Sanofi: SWOT Analysis
Figure 8.8 Medtronic: SWOT Analysis
Figure 8.9 Apotex: SWOT Analysis
Figure 8.10 A: SWOT Analysis
Figure 10.1: Global Overactive Bladder Therapeutic Market: SWOT Analysis
Figure 10.2: Global Overactive Bladder Therapeutic Market: Porter’s Five Forces Analysis
Figure 12.1 Global Overactive Bladder Therapeutic Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 12. 2 Global Overactive Bladder Therapeutic Market by Region: Market Share 2017 (%)
Figure 12.3 Prevalence of Overactive Bladder Syndrome versus Other Major Health Condition
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
